Hohhot strengthens biopharmaceutical innovation

Hohhot, capital of North China's Inner Mongolia autonomous region, is rapidly emerging as a national leader in biopharmaceutical innovation, becoming the first city in China to advance a subunit African swine fever vaccine into clinical evaluation, highlighting its growing biotech research and development strengths.

The city has achieved numerous scientific breakthroughs, including the establishment of the world's first intelligent manufacturing project for mRNA vaccines and nucleic acid drugs in Hohhot and a smart production line for pet vaccines, with an annual capacity of 8 million doses, which has passed GMP static acceptance.

Hohhot's biopharmaceutical industry output rose from 13.11 billion yuan ($1.82 billion) in 2020 to 20.25 billion yuan in 2024. The city is now home to 117 R&D institutions and holds 602 approved drug registration certificates. It has also added two regional leading enterprises and seven high-tech leading companies, gradually building a competitive edge in animal vaccine development.

This year, Hohhot has been working toward becoming a national hub for veterinary vaccine research and development. The city is attracting top talent and research teams from the Chinese Academy of Sciences, Tsinghua University, and Guangzhou Laboratory, with local companies being supported in accelerating the development and commercialization of new animal vaccines.